-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
Remi Rabeuf, Director Corporate Alliances & Strategic Partnerships, talks us through his role, driving and coordinating activities to bring our Nu.Q® NETs assay into the clinical and diagnostics market. This includes product development, gathering clinical evidence, regulatory approval, and increasing awareness and availability.
Remi also highlights the importance of working with key opinion leaders and centres of excellence to generate data and ensure successful market adoption for our Nu.Q® NETs test.
“What I find very exciting is that we are the first company having a NET biomarker launch in the field that can help practitioners to improve sepsis management. We can contribute to improve mortality and comorbidities for those patients and contribute to save lives.”
Remi Rabeuf
Volition Life Cycle Leader
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields